Asunercept companion diagnostic - Amoy Diagnostics/CANbridge Life Sciences

Drug Profile

Asunercept companion diagnostic - Amoy Diagnostics/CANbridge Life Sciences

Alternative Names: Asunercept companion diagnostic - CANbridge Life Sciences/Amoy Diagnostics; CAN 008 companion diagnostic - Amoy Diagnostics/CANbridge Life Sciences; CAN 008 companion diagnostic - CANbridge Life Sciences/Amoy Diagnostics

Latest Information Update: 02 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amoy Diagnostics
  • Developer Amoy Diagnostics; CANbridge Life Sciences
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 16 May 2017 Early research in Undefined indication (Diagnosis) in China
  • 16 May 2017 CANbridge Life Sciences and Amoy Diagnostics collaborate to develop companion diagnostics for asunercept
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top